**[404] EMENDO BIOTHERAPEUTICS - GENOME EDITING COMPANY**

**David Baram1, 1 Emendo Biotherapeutics**

* **Investment Rational**

Emendo develops biotherapeutics based on its novel gene editing tools.

# Leveraging our expertise in protein engineering, we utilize random and rational methodologies to redesign genome editing tools, and to open new areas of therapeutics thus far unavailable due to inherent limitations.

The Emendo team includes experienced and leading investors, charismatic management and highly skilled scientific team, all together bringing vision, talent, experience and multidisciplinarity to our R&D process.

* **Business Strategy**

# Emendo will generate near term revenues from out-licensing its platform technology and at the same time develop its own product line of novel biotherapeutics. Long term revenues will come from new therapeutic products that will target various genetic disorders.

* **Core Technology**

Based on proven track record of its team, Emendo utilizes advanced protein engineering technologies to develop new gene editing tools:

* Design specific nuclease per target, using fused elements that enhance homology directed repair (HDR) after genome cleavage, to increase efficiency and reduce off-target.
* Engineered recombination tools configured to cleave, insert a donor DNA into a sequence specific target, and re-ligate, without utilizing or activating the cell repair mechanism.
* **Product Profile/Pipeline**
* Emendo is currently developing several tools that will be used as its platform technology in the near future. *In-vivo* POC for these machines is planned for the first half of 2017. At the same time, Emendo designs its tools to be highly specific for various clinical conditions. Aiming for *ex-vivo* POC in target cells during the first half of 2017, and first in men by the end of 2018
* Product line:

1. Highly efficient *ex-vivo* editing in stem cells based on its novel HDR enhanced, ultra specific Cas9 for various medical conditions.

2. *In-vivo* knock in of whole genes using a novel RNA guided, recombination oriented molecular machine.

* **What's Next?**

Completed $10M series A round in 2016. Planning series B Round for the second half of 2017 after In-vivo POC. Expanding the scientific team and R&D resources.